Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Immunological characterization of glioblastoma cells for immunotherapy.

Jung TY, Choi YD, Kim YH, Lee JJ, Kim HS, Kim JS, Kim SK, Jung S, Cho D.

Anticancer Res. 2013 Jun;33(6):2525-33.

PMID:
23749904
2.

[Expression of HLA class I molecules and MHC class I chain-related molecules A/B in K562 and K562/AO2 cell lines and their effects on cytotoxicity of NK cells].

Mei JZ, Niu XQ, Guo KY, Zhou J, Wei HM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Apr;15(2):288-91. Chinese.

PMID:
17493333
3.

Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand.

Oh SJ, Yang JI, Kim O, Ahn EJ, Kang WD, Lee JH, Moon KS, Lee KH, Cho D.

Cancer Cell Int. 2017 Feb 10;17:22. doi: 10.1186/s12935-017-0397-7. eCollection 2017.

4.
5.

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S.

Blood. 2005 Jan 1;105(1):251-8. Epub 2004 Aug 24.

6.

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS.

J Natl Cancer Inst. 2015 Dec 6;108(5). doi: 10.1093/jnci/djv375. Print 2016 May.

PMID:
26640245
7.

Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.

Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A.

Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098.

8.

The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.

Höring E, Podlech O, Silkenstedt B, Rota IA, Adamopoulou E, Naumann U.

Anticancer Res. 2013 Apr;33(4):1351-60.

PMID:
23564772
9.

Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.

Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC, Ohlfest JR.

J Neurooncol. 2007 Jun;83(2):121-31. Epub 2006 Nov 1. Erratum in: J Neurooncol. 2007 Jun;83(2):133.

PMID:
17077937
10.

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A.

Cancer Res. 2002 Nov 1;62(21):6178-86.

11.

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM.

Cytotherapy. 2012 Oct;14(9):1131-43. doi: 10.3109/14653249.2012.700767. Epub 2012 Aug 17.

12.

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A.

J Immunother. 2015 Jun;38(5):197-210. doi: 10.1097/CJI.0000000000000082.

13.

Interleukin 10 decreases MICA expression on melanoma cell surface.

Serrano AE, Menares-Castillo E, Garrido-Tapia M, Ribeiro CH, Hernández CJ, Mendoza-Naranjo A, Gatica-Andrades M, Valenzuela-Diaz R, Zúñiga R, López MN, Salazar-Onfray F, Aguillón JC, Molina MC.

Immunol Cell Biol. 2011 Mar;89(3):447-57. doi: 10.1038/icb.2010.100. Epub 2010 Aug 17.

PMID:
20714339
14.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

15.

The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.

Belicha-Villanueva A, Riddell J, Bangia N, Gollnick SO.

Lasers Surg Med. 2012 Jan;44(1):60-8. doi: 10.1002/lsm.21160. Epub 2012 Jan 3.

16.
17.

Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction.

Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L.

Neoplasia. 2009 Jul;11(7):662-71.

18.

Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.

Mingari MC, Vitale C, Cantoni C, Bellomo R, Ponte M, Schiavetti F, Bertone S, Moretta A, Moretta L.

Eur J Immunol. 1997 Jun;27(6):1374-80.

PMID:
9209487
19.

Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.

Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M, Imamura M.

Leukemia. 2007 Oct;21(10):2103-8. Epub 2007 Jul 12.

PMID:
17625602
20.

Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.

Gong W, Xiao W, Qian L, Gong C, Hu M, Pan X, Ji M.

Cell Mol Immunol. 2010 Nov;7(6):477-84. doi: 10.38/cmi.2010.41. Epub 2010 Sep 27.

Supplemental Content

Support Center